| Product Name | MF | CAS | Details |
|---|
| Telisotuzumab vedotin | 1714088-51-3 | Details |
| Cantuzumab ravtansine | 868747-45-9 | Details |
| Carotuximab-MMAE | Details |
| Cetuximab-MMAE | Details |
| Clivatuzumab-MMAE | Details |
| Codrituzumab-MMAE | Details |
| Datopotamab deruxtecan | Details |
| Disitamab vedotin | 2136633-23-1 | Details |
| Enapotamab vedotin | 1912424-97-5 | Details |
| Enfortumab vedotin-ejfv | Details |
| Glembatumumab vedotin | Details |
| Ladiratuzumab vedotin | 1629760-29-7 | Details |
| Indusatumab vedotin | 1514889-12-3 | Details |
| Labetuzumab govitecan | 1469876-18-3 | Details |
| Laprituximab emtansine | 1622327-37-0 | Details |
| Lifastuzumab vedotin | 1401812-88-1 | Details |
| Loncastuximab tesirine | 1879918-31-6 | Details |
| Lorvotuzumab mertansine | 1008106-64-6 | Details |
| Lorvotuzumab-MMAE | Details |
| Mirvetuximab soravtansine | 1453084-37-1 | Details |
| Mirvetuximab-MMAE | Details |
| Murlentamab-MMAE | Details |
| Patritumab deruxtecan | Details |
| Pinatuzumab vedotin | 1313706-14-7 | Details |
| Praluzatamab ravtansine | Details |
| Praluzatamab-MMAE | Details |
| Rosopatamab-MMAE | Details |
| Sacituzumab govitecan | 1491917-83-9 | Details |
| Serclutamab talirine | 2140174-56-5 | Details |
| Sirtratumab vedotin | 1824663-83-3 | Details |
| Sofituzumab vedotin | 1418200-58-4 | Details |
| Talacotuzumab-MMAE | Details |
| Tisotumab vedotin | 1418731-10-8 | Details |
| Trastuzumab deruxtecan | 1826843-81-5 | Details |
| Trastuzumab emtansine | 1018448-65-1 | Details |
| Tusamitamab-MMAE | Details |
| Vadastuximab talirine | 1436390-64-5 | Details |
| Vorsetuzumab mafodotin | 1165741-01-4 | Details |
| Zilovertamab vedotin | Details |
| Human NK cell robust expansion kit | Details |
| DHG-9140A | Details |
| Firefly Luciferase Reporter Gene Assay Kit | Details |
| Human 5HT1A VLP | Details |
| Human 5HT1B VLP | Details |
| Human 5HT1D VLP | Details |
| Human 5HT1E VLP | Details |
| Human 5HT1F VLP | Details |
| Human 5HT2A VLP | Details |
| Human 5HT2B VLP | Details |
| Human 5HT2C VLP | Details |
| Human ADGRG7 VLP | Details |
| Human ADGRL1 VLP | Details |
| Human ADGRL2 VLP | Details |
| Human ADGRL3 VLP | Details |
| Human ADGRL4 VLP | Details |
| Human ADGRV1 VLP | Details |
| Human ADORA1 VLP | Details |
| Human ADORA2B VLP | Details |
| Human ADORA3 VLP | Details |
| Human ADRA1A VLP | Details |
| Human 5HT4R VLP | Details |
| Human 5HT5A VLP | Details |
| Human 5HT7R VLP | Details |
| Human ACKR1 VLP | Details |
| Human ADA2B VLP | Details |
| Human ADGRA1 VLP | Details |
| Human ADGRA2 VLP | Details |
| Human ADGRA3 VLP | Details |
| Human ADGRB1 VLP | Details |
| Human ADGRB2 VLP | Details |
| Human ADGRB3 VLP | Details |
| Human ADGRD1 VLP | Details |
| Human ADGRD2 VLP | Details |
| Human ADGRE1 VLP | Details |
| Human ADGRE2 VLP | Details |
| Human ADGRE3 VLP | Details |
| Human ADGRF2 VLP | Details |
| Human ADGRF4 VLP | Details |
| Human ADGRG2 VLP | Details |
| Human ADGRG4 VLP | Details |
| Human ADGRG5 VLP | Details |
| Human ADGRG6 VLP | Details |
| Human ADGRG3 VLP | Details |
| Human ADGRF5 VLP | Details |
| Human ADGRF3 VLP | Details |
| Human ADGRE5 VLP | Details |
| Human ADCYAP1R1 VLP | Details |
| Human ACKR2 VLP | Details |
| Human A2AR VLP | Details |
| Human 5HT5B VLP | Details |
| Tilvestamab-MMAE | Details |
| Ozuriftamab vedotin | Details |
| Farletuzumab-MMAE | Details |
| Human ADGRG1 VLP | Details |
| Human ADGRF1 VLP | Details |
| Human ACKR4 VLP | Details |
| Human 5HT6R VLP | Details |
| Buffer | C6H7KO7 | Details |
| Tusamitamab ravtansine | Details |
| Polatuzumab vedotin-piiq | Details |
| Product Total： Product Page： | ||||
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 | ||||